腺苷 5'-三磷酸酯-gamma-32P | 2964-07-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 中文名称: 腺苷 5'-三磷酸酯-gamma-32P
• 中文别名: 腺苷5'-三磷酸酯-gamma-32P
• 英文名称: ATP
• 英文别名: [γ³²P]ATP；[γ-32P]-adenosine-5'-triphosphate；adenosine 5'-triphosphoric acid；γ[³²P]-ATP；[γ-³²P]ATP；[gamma-³²P]ATP；[gamma-32P]-ATP；[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxy(32P)phosphoryl hydrogen phosphate
• CAS: 2964-07-0
• 化学式: C₁₀H₁₆N₅O₁₃P₃
• 分子量: 508.21
• InChiKey: ZKHQWZAMYRWXGA-KNYAHOBESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.7
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  279
• 氢给体数：
  7
• 氢受体数：
  17

反应信息

• 作为反应物：
  描述：

  [(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-[[[(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-[[hydroxy-[(2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl] acetate 、 腺苷 5'-三磷酸酯-gamma-32P 生成 [(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-[[[(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-[[[(2R,3S,5R)-2-((32P)dihydroxy(32P)phosphoryloxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl] acetate
  参考文献：
  名称：

  TAKTAKISHVILI, M. O.;LEBEDENKO, E. N., XIMIYA I XIM. TEXNOL., TBILISI,(1988) S. 72-78

  摘要：

  DOI：
• 作为试剂：
  描述：

  D-核糖 在 pyruvate kinase 、 腺苷 5'-三磷酸酯-gamma-32P 、 magnesium chloride 作用下， 反应 1.0h， 生成 [5-(32)P]ribose 5-phosphate
  参考文献：
  名称：

  Loop Residues and Catalysis in OMP Synthase

  摘要：

  Residue-to-alanine mutations and a two-amino acid deletion have been made in the highly conserved catalytic loop (residues 100-109) of Salmonella typhimurium OMP synthase (orotate phosphoribosyltransferase, EC 2.4.2.10). As described previously, the K103A mutant enzyme exhibited a 10(4)-fold decrease in k(cat)/K-M for PRPP; the K100A enzyme suffered a 50-fold decrease. Alanine mutations at His105 and Glu107 produced 40- and 7-fold decreases in k(cat)/K-M, respectively, and E101A, D104A, and G106A were slightly faster than the wild-type (WT) in terms of k(cat), with minor effects on k(cat)/K-M. Equilibrium binding of OMP or PRPP in binary complexes was affected little by loop mutation, suggesting that the energetics of ground-state binding have little contribution from the catalytic loop, or that a favorable binding energy is offset by costs of loop reorganization. Pre-steady-state kinetics for mutants showed that K103A and E107A had lost the burst of product formation in each direction that indicated rapid on-enzyme chemistry for WT, but that the burst was retained by H105A. Delta 102 Delta 106, a loop-shortened enzyme with Ala102 and Gly106 deleted, showed a 10(4)-fold reduction of k(cat) but almost unaltered K-D values for all four substrate molecules. The 20% (i.e., 1.20) intrinsic [1'-H-3]OMP kinetic isotope effect (KIE) for WT is masked because of high forward and reverse commitment factors. K103A failed to express intrinsic KIEs fully (1.095 +/- 0.013). In contrast, H105A, which has a smaller catalytic lesion, gave a [1'-3H]OMP KIE of 1.21 +/- 0.0005, and E107A (1.179 +/- 0.0049) also gave high values. These results are interpreted in the context of the X-ray structure of the complete substrate complex for the enzyme [Grubmeyer, C., Hansen, M. R., Fedorov, A. A., and Almo, S. C. (2012) Biochemistry 51 (preceding paper in this issue, DOI 10.1021/bi300083p)]. The full expression of KIEs by H105A and E107A may result from a less secure closure of the catalytic loop. The lower level of expression of the KIE by K103A suggests that in these mutant proteins the major barrier to catalysis is successful closure of the catalytic loop, which when closed, produces rapid and reversible catalysis.

  DOI：

  10.1021/bi300082s

文献信息

• Purified human ceramide-activated protein kinase
  申请人：Sloan-Kettering Institute for Cancer Research

  公开号：US05451518A1

  公开（公告）日：1995-09-19

  A membrane-bound ceramide-activated protein kinase has been purified from human cells. The protein kinase has an apparent molecular weight of about 95 kD and specifically phosphorylates the threonine residue in a polypeptide containing Pro-Leu-Thr-Pro (SEQID NO:1).

  一种膜结合的鞘脂激活蛋白激酶已从人类细胞中纯化。该蛋白激酶的表观分子量约为95 kD，并特异性磷酸化包含Pro-Leu-Thr-Pro（SEQID NO：1）的多肽中的苏氨酸残基。
• High level expression of basic fibroblast growth factor having a
  申请人：California Biotechnology Inc.

  公开号：US05143829A1

  公开（公告）日：1992-09-01

  DNA sequences are provided which encode a form of basic fibroblast growth factor lacking one of the alanine residues immediately following the N-terminal methionine residue of the primary translation product. The DNA sequences can be expressed to produce basic fibroblast growth factor having a homogeneous N-terminus.

  提供了编码一种基础成纤维细胞生长因子的DNA序列，该成纤维细胞生长因子缺少原始翻译产物N-末端甲硫氨酸残基后紧接着的一个丙氨酸残基。这些DNA序列可以被表达，以产生具有均一N-末端的基础成纤维细胞生长因子。
• Assay for identifying agents which act on the ceramide-activated protein
  申请人：Sloan-Kettering Institute for Cancer Research

  公开号：US06040149A1

  公开（公告）日：2000-03-21

  The subject invention provides a purified membrane-bound ceramide-activated protein kinase having an apparent molecular weight of about 110 kD as determined by SDS polyacrylamide gel electrophoresis, which protein kinase is capable of specifically phosphorylating the threonine residue in a Thr-Pro- or a Thr-Leu-Pro-containing polypeptide. The subject invention also provides a method of determining whether an agent is capable of specifically inhibiting the phosphorylation activity of the ceramide-activated protein kinase. The subject invention further provides a method of determining whether an agent is capable of specifically stimulating the phosphorylation activity of the ceramide-activated protein kinase. The subject invention further provides a method of treating a subject having an inflammatory disorder. The subject invention further provides a method of treating a human subject infected with HIV so as to reduce the proliferation of HIV in the human subject. The subject invention further provides a method of treating a subject having a disorder associated with poor stem cell growth. The subject invention further provides a method of determining whether an agent is capable of specifically inhibiting the ability of lipopolysaccharide to stimulate the phosphorylation activity of the ceramide-activated protein kinase of the subject invention. Finally, the subject invention provides a method of treating a subject suffering from a lipopolysaccharide-related disorder.

  本发明提供了一种纯化的膜结合鞘氨醇激活的蛋白激酶，其表观分子量约为110 kD，经SDS聚丙烯酰胺凝胶电泳确定，该蛋白激酶能够特异性磷酸化含有Thr-Pro或Thr-Leu-Pro多肽中的苏氨酸残基。本发明还提供了一种确定某种药物是否能够特异性抑制鞘氨醇激活的蛋白激酶磷酸化活性的方法。本发明还提供了一种确定某种药物是否能够特异性刺激鞘氨醇激活的蛋白激酶磷酸化活性的方法。本发明还提供了一种治疗患有炎症性疾病的受试者的方法。本发明还提供了一种治疗人类感染HIV以减少HIV在人体内增殖的方法。本发明还提供了一种治疗与干细胞生长不良相关的受试者的方法。本发明还提供了一种确定某种药物是否能够特异性抑制脂多糖刺激本发明中鞘氨醇激活的蛋白激酶磷酸化活性的能力的方法。最后，本发明提供了一种治疗患有脂多糖相关疾病的受试者的方法。